Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 29 ... in patients who were 65 years or older and diagnosed with colon, non-small cell lung, or breast cancer or diffuse large B-cell lymphoma in 1991-2002. Patients were identified in the ... during chemotherapy; however, concerns about the risks of venous thromboembolism (the disease that includes deep vein thrombosis and pulmonary embolism) and mortality ...
2009 NOV 24 ... in developing PET system. In addition, Aurora developed the AURORA Spiral RODEO™ Breast, the first and currently the only FDA-certified magnetic resonance imaging (MRI) ... Taiwan, Technology, Diagnosis, Diagnostics. This article was prepared by Disease Prevention Week editors from staff and other reports. Copyright 2009, Disease ...
2009 NOV 23 ... P2rx7(-/-) or Nlrp3(-/-) or Casp1(-/-) hosts. Anthracycline-treated individuals with breast cancer carrying a loss-of-function allele of P2RX7 developed metastatic disease more ...
2009 NOV 23 ... possible contributors to SSIs in a cohort of patients who underwent surgery for breast cancer. All breast surgeries performed between January 2001 and December 2005 were ... information, contact D. Vilarcompte, Institute Nacl Cancerol, Dept. of Infectious Disease, Av San Fernando 22, Col Secc XVI, Mexico City 14080, DF, Mexico. Publisher ...
2009 NOV 23 ... node biopsy after neoadjuvant chemotherapy feasible in Chinese patients with invasive breast cancers,' are detailed in a study published in ANZ Journal of Surgery. "A wide ... SLNB is feasible and applicable in Chinese patients with breast cancer with operable disease who have received neoadjuvant chemotherapy." Cheung and colleagues ...
2009 NOV 23 ... bound paclitaxel has demonstrated an activity and an improved toxicity profile in breast and lung cancers. Five patients with gynecologic cancers (2 ovarian, 2 endometrial, and ... Drug Therapy, Drugs, Gynecologic Cancer, Gynecology, Hypersensitivity, Infectious Disease, Lung Cancer, Lung Neoplasms, Oncology, Paclitaxel, Pharmaceuticals, Pulmonology, ...
2009 NOV 23 ... (Potential Role of Tissue Microarrays for the Study of Biomarker Expression in Benign Breast Disease and Normal Breast Tissue. Applied Immunohistochemistry & Molecular Morphology, ...
2009 NOV 23 ... "Sentinel lymph node (SLN) surgery is widely used for nodal staging in early-stage breast cancer This study was pet-formed to evaluate the accuracy of SLN surgery for patients ... Adjusting for clinical stage revealed no differences in local-regional recurrences, disease-free or overall survival between groups Conclusions: SLN surgery after chemotherapy is ...
2009 NOV 23 ... United States conducted a study "To assess the feasibility of percutaneous multiprobe breast cryoablation (BC) for diverse presentations of cancers that remained in situ after BC. ... who refused surgery by using multiple 2.4-mm cryoprobes. Five patients had recurrent disease and six had new diagnoses. With use of only local anesthesia, six patients were treated ...
2009 NOV 23 ... methotrexate and 5-fluorouracile (CMF)-based chemotherapy for adjuvant treatment of breast cancer reduces the risk of relapse. In this exploratory study, we tested the feasibility ... discriminate between patients who would experience relapse and patients who would remain disease-free. An additional independent validation set of 51 patients and 21 genes were analyzed ...
2009 NOV 23 ... II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatment,' is the subject of a report. ... for Adverse Events (CTCAE) version 3.0, overall response rate (RR), time to progression disease and overall survival time. Gemcitabine 1250 mg/m2 was determined as the dose for Step 2. ...
2009 NOV 23 ... of family and friends in surgical treatment choices. Women diagnosed with nonmetastatic breast cancer from June 2005 through February 2007 and reported to the Los Angeles or Detroit ... rate was 72.4%. The analytic sample (N = 1651) excluded those with stage IIIA or higher disease, self-reported clinical contraindications to breast-conserving surgery with radiation, ...
2009 NOV 23 ... GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb -- were the highest-selling drug class in breast cancer treatment. Continued uptake of Herceptin and Tykerb/Tyverb and the expected ... percent from 2008 to 2018, largely owing to greater uptake by patients with metastatic disease. "Since its approval, Avastin has garnered substantial patient share in ...
2009 NOV 23 ... three years since physicians began offering SAVI™ radiation treatment as part of breast conservation therapy for early-stage breast cancer - a major milestone in breast ... We are proud that our technology gives patients and physicians more options to address a disease that impacts one out of every eight women in the United States each year," said Jill ...
2009 NOV 23 ... aromatase inhibitors: what the general internist needs to know,' is now available. "Breast cancer patients represent the largest group of adult cancer survivors in the US. Most ... FDA approved for use in the US. All have been shown to be superior to tamoxifen in disease free survival (DFS) in the treatment of both metastatic and early breast cancers. While ...
2009 NOV 23 ... Park, Abingdon, Oxford OX14 4RN United Kingdom. Keywords: Finland, Pori, Breast Disease Therapy, Antineoplastic, Breast Disease, Breast Pain, ...
2009 NOV 23 ... "Squamous cell carcinoma (SCC) of the breast is an uncommon breast neoplasm. There are limited data about its epidemiology and few ... the years 1988 to 2006. At the time of diagnosis, 53 per cent of patients had localized disease, 32 per cent of patients had regional lymph node or locally advanced disease, and 8 per ...
2009 NOV 23 ... According to recent research published in the journal Breast Cancer Research and Treatment, "The p53 tumor suppressor gene has a central role in the ... relevance in codon 72 heterozygous breast cancer patients (i.e., survival and age of disease onset). 199 postmenopausal cases were analyzed for LOH using MegaBACE(1000) and ...
2009 NOV 23 ... According to a study from the United States, "HER2 amplification in breast cancer is associated with a more aggressive disease, greater likelihood of recurrence, ...
2009 NOV 23 ... Larry Norton. The Company expects to initiate a Phase I/II study of oral indibulin in breast cancer patients employing this dosing schedule established preclinically. Once the ... very promising, indicating a potentially new drug to help control this life-threatening disease with acceptable safety and quality of life," commented George Demetri, MD, Director of ...
